US Stock Market Move | Tesla, Inc. (TSLA.US) fell by 5%, with Tesla, Inc.'s sales in China hitting a 3-year low in October.
On Thursday, Tesla (TSLA.US) extended its decline to 5%, down 10% from its monthly peak at the beginning of the month, now trading at $409.08.
On Thursday, Tesla, Inc. (TSLA.US) saw its decline widen to 5%, with a cumulative decline of 10% from its high point at the beginning of the month, now trading at $409.08. In terms of news, Tesla, Inc. in China delivered its worst performance in three years in October. The retail sales of Tesla, Inc. in China in October were 26,006 vehicles, a decrease of 63.64% from September's 71,525 vehicles, and a 35.76% decrease from the same period in 2024, marking the lowest level since November 2022.
In addition, according to sources, the head of Tesla, Inc.'s artificial intelligence (AI) business reportedly told employees in an internal speech that 2026 will be "the most difficult year of their lives." Some employees described the meeting as a "rallying call." The meeting lasted for nearly two hours, with several leaders from the AI department giving speeches. Employees were informed about the aggressive production schedule of OptimusSiasun Robot & Automation, as well as the specific goals of the Robotaxi self-driving taxi service. Analysts point out that Tesla, Inc.'s AI projects like OptimusSiasun Robot & Automation have yet to generate revenue, leading to questions about the stock valuation.
Related Articles

On March 31st, STANCHART (02888) spent 15.3417 million pounds to repurchase 984,000 shares.

POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.

Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.
On March 31st, STANCHART (02888) spent 15.3417 million pounds to repurchase 984,000 shares.

POP MART (09992) spent 99.44596 million Hong Kong dollars on April 1st to repurchase 670,000 shares.

Shanghai Fosun Pharmaceutical's subsidiary drug HLX319 has received approval for clinical trials.






